Novo Nordisk is capitalizing on a significant growth opportunity as the European Medicines Agency recommends the use of its semaglutide-based weight loss drug for adolescents aged 12 and older. The company's shares have risen 43% over the past year, driven by increased earnings per share estimates for 2023 and a projected revenue of $29.9 billion, reflecting a robust 19.5% year-on-year increase. With a strategic share repurchase program in place, Novo Nordisk is reinforcing its financial strength amid rising competition from potential rivals like Viking.
“European Medicines Agency · recommended expanding the use of · Novo Nordisk's weight loss drug · in adolescents aged 12 years and older”
“Novo Nordisk's weight loss drug · is based on · semaglutide”
“Novo Nordisk · has a Zacks Rank · #1 (Strong Buy)”
“Earnings per share estimates for NVO · have increased · for 2023 · $4.18 to $4.49”
“NVO's shares · have gained · in the past year · 40%”
“Novo Nordisk · is likely to be · the biggest benefactor of Ozempic's popularity”
“Viking · could have · a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro · in the making”
“NVO shares · are up · 0.64% · $156.32 on the last check Wednesday”
“Earnings per share estimates for NVO · have increased · from $4.18 to $4.49 for 2023”
“NVO's shares · have gained · 41% · in the past year”
“Novo Nordisk · closed at · $155.32 · +0.4% move from the previous day”
“Novo Nordisk · gained · 7.91% · over the past month”
